aromatase inhibitors

ASCO Highlight: Another Treatment Option for ER-Positive Breast Cancer

Earlier this year, a new treatment option was added to the arsenal for ER-positive breast cancer in postmenopausal women when the U.S. Food and Drug Administration (FDA) approved the combination of letrozole (Femara) and palbociclib (Ibrance).